Evidence map›Paper›PMID 40888924›Full record

SynthesisRheumatology international2025

Small extracellular vesicle cargo as biomarkers in autoimmune rheumatic diseases: a systematic review.

Michail K Chatzopoulos, George E Fragoulis, Martina Samiotaki, Maria G Tektonidou, Petros P Sfikakis, Eleni-Kyriaki Vetsika

Abstract readSystematic Review
In one paragraph

Synthesis in Rheumatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Michail K ChatzopoulosFirst Department of Propaedeutic Internal Medicine, Joint Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.ORCID http://orcid.org/0009-0007-7198-9919
George E FragoulisFirst Department of Propaedeutic Internal Medicine, Joint Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.ORCID http://orcid.org/0000-0003-4932-7023
Martina SamiotakiInstitute for Bio-innovation, Biomedical Sciences Research Center "Alexander Fleming", Vari, 16672, Greece.ORCID http://orcid.org/0000-0001-9952-0636
Maria G TektonidouFirst Department of Propaedeutic Internal Medicine, Joint Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.ORCID http://orcid.org/0000-0003-2238-0975
Petros P SfikakisFirst Department of Propaedeutic Internal Medicine, Joint Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.ORCID http://orcid.org/0000-0001-5484-2930
Eleni-Kyriaki VetsikaCentre of New Biotechnologies and Precision Medicine (CNBPM), School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. ekvetsika@med.uoa.gr.ORCID http://orcid.org/0000-0002-3994-1583

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increasing evidence has shown the role of small extracellular vesicles (sEVs) in autoimmune rheumatic diseases (ARDs). This systematic literature review aims to evaluate the role of sEVs as biomarkers in ARDs, focusing on their molecular cargo and their utility for disease diagnosis, monitoring, and treatment response. A systematic search was conducted in MEDLINE/PubMed and Scopus from inception until July 2025, using the search terms; [(small extracellular vesicles) or exosomes) and ((rheumatic disease) or (rheumatoid arthritis) or (psoriatic arthritis) or (axial spondylarthritis) or (ankylosing spondylitis) or (systemic lupus erythematosus) or (Sjögren's syndrome) or scleroderma or (systemic sclerosis) or myositis or polymyositis)]. Eligible studies were those reporting on sEV isolation from patient samples and comparing it with healthy individuals or controls with non-inflammatory conditions. The initial search yielded 1593 results, and 46 studies met the inclusion criteria. Literature reviews revealed that miRNAs and long non-coding (lnc)RNAs isolated from sEVs might serve as potential biomarkers for disease activity and treatment response in ARDs, mainly in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). In addition, sEV miRNA-21 and miRNA-146a have been often described in studies in SLE patients, indicating their potential role in differentiating SLE from healthy individuals. Although proteomic studies identified disease-specific proteins within sEVs, there is no consensus among the limited studies reporting sEV proteins. Although numerous studies have examined the role of sEVs in ARDs, there is a lack of consensus in the findings. Further research using well-standardized methodologies is needed to ensure reliable and reproducible results. PROSPERO 2025 CRD420250646438. Available from https://www.crd.york.ac.uk/PROSPERO/view/CRD420250646438 .

Indexed as

Autoimmune DiseasesExtracellular VesiclesRheumatic DiseasesBiomarkersHumansMicroRNAsRNA, Long NoncodingBiomarkersMicroRNAsRNA, Long NoncodingDifferential diagnosisExtracellular vesiclesPrognosisRheumatic diseasesRheumatoid arthritisSystemic lupus erythematosus

Identifiers

PMID40888924
PMCPMC12402020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.